2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 67.050 | 83.927 | 112.117 | 99.963 | 26.407 | 0 | 0 | 0 | 0 | - |
Total Income - EUR | 67.077 | 84.863 | 112.453 | 101.877 | 26.435 | 172 | 0 | 0 | 0 | - |
Total Expenses - EUR | 70.331 | 73.319 | 91.433 | 99.781 | 33.806 | 3.297 | 0 | 0 | 0 | - |
Gross Profit/Loss - EUR | -3.254 | 11.545 | 21.020 | 2.096 | -7.371 | -3.126 | 0 | 0 | 0 | - |
Net Profit/Loss - EUR | -3.254 | 11.545 | 19.356 | 864 | -7.636 | -3.131 | 0 | 0 | 0 | - |
Employees | 3 | 3 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | - |
Check the financial reports for the company - Origo Pharma S.r.l.
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 2.519 | 1.881 | 1.209 | 8.032 | 0 | 0 | 0 | 0 | 0 | - |
Current Assets | 38.778 | 32.775 | 20.074 | 17.797 | 3.472 | 169 | 166 | 162 | 163 | - |
Inventories | 10.470 | 21.173 | 7.593 | 10.337 | 241 | 0 | 0 | 0 | 0 | - |
Receivables | 27.442 | 9.985 | 9.239 | 6.149 | 251 | 166 | 163 | 159 | 160 | - |
Cash | 866 | 1.616 | 3.242 | 1.311 | 2.980 | 3 | 3 | 3 | 3 | - |
Shareholders Funds | -24.590 | -13.250 | 6.241 | 6.999 | -765 | -3.881 | -3.807 | -3.723 | -3.735 | - |
Social Capital | 223 | 225 | 223 | 219 | 215 | 211 | 207 | 202 | 203 | - |
Debts | 65.887 | 47.906 | 15.043 | 18.830 | 4.237 | 4.050 | 3.973 | 3.885 | 3.897 | - |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4690 - 4690" | |||||||||
CAEN Financial Year |
4690
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Origo Pharma S.r.l.